Determination of the cut-off prothrombin time to estimate plasma rivaroxaban overdose status
- 16 Downloads
Laboratory monitoring of rivaroxaban (RIV) is required under certain conditions. Mass spectrometry and anti-factor Xa assays are the recommended methods, which may not be readily available. Prothrombin time (PT) is the most widely used and simple coagulation assay. To set the cutoff PT and international normalized ratio (INR) to estimate RIV overdose status. RIV-spiked pooled normal plasma was used. PT test was performed using a CA-7000 coagulometer and Thromborel S reagent. The precise measurement of RIV concentration at the cut-off PT was evaluated according to the Clinical and Laboratory Standard Institute (CLSI) EP12-A2 guideline. The RIV concentration at 275 ng/mL was analyzed using 40 replicates. Receiver operating characteristic (ROC) analysis was performed to determine the cutoff value for the determination of RIV potential overdose status. An imprecision estimation of PT was conducted with 220.00 ng/mL, 247.50 ng/mL, 261.25 ng/mL, 288.75 ng/mL, 302.50 ng/mL and 330.00 ng/mL concentrations of RIV in 60 replicates. According to the ROC analysis, the cutoff clotting times and INR values to determine the overdose status of RIV were 13.45 s and 1.39. With these values, there was a 92.6% probability that plasma samples with RIV concentration ≤ 247.50 ng/mL yielded consistently negative (on-therapy dose) results, and those with ≥ 302.50 ng/mL yield consistent positive (potential overdose) results using our PT assay. PT with a reliable cutoff clotting time and INR can be used to determine the potential overdose status of RIV to facilitate the diagnosis and treatment by controlling the dose.
KeywordsProthrombin time Rivaroxaban Cutoff Overdose Anticoagulant
B. Kim performed research, analyzed and interpreted data, performed statistical analysis, and wrote the manuscript. S. Jang designed research, analyzed and interpreted data. Y.J. Lee and N. Park performed research. Y.U. Cho and C.J. Park analyzed and interpreted data.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest with the contents of this article.
- 5.Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM, van der Graaf F, Brunsveld L, van de Kerkhof D (2014) Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 12(10):1636–1646. https://doi.org/10.1111/jth.12702 CrossRefGoogle Scholar
- 6.Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, Guillermo C, Kawai Y, Lindhoff-Last E, Kitchen S (2018) International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 118(3):437–450. https://doi.org/10.1055/s-0038-1627480 CrossRefGoogle Scholar
- 9.Samama MM, Contant G, Spiro TE, Perzborn E, Flem LL, Guinet C, Gourmelin Y, Martinoli JL, Rivaroxaban Prothrombin Time Field Trial Laboratories (2012) Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb/Hemost Off J Int Acad Clin Appl Thromb/Hemost 18(2):150–158. https://doi.org/10.1177/1076029611426282 CrossRefGoogle Scholar
- 10.Camici GG, Steffel J, Akhmedov A, Schafer N, Baldinger J, Schulz U, Shojaati K, Matter CM, Yang Z, Luscher TF, Tanner FC (2006) Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. Circulation 114(14):1512–1521. https://doi.org/10.1161/circulationaha.106.638460 CrossRefGoogle Scholar
- 11.Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61(12):873–880. https://doi.org/10.1007/s00228-005-0043-5 CrossRefGoogle Scholar
- 12.Clinical and Laboratory Standard Institute (2008) User protocol for evaluation of qualitative test performance; Approved Guideline-Second Edition (EP12-A2). CLSI, WayneGoogle Scholar
- 13.Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, Gent M, Haas S, Huisman MV, Kakkar AK, Kalebo P, Kwong LM, Misselwitz F, Turpie AG (2008) Population pharmacokinetics and pharmacodynamics of rivaroxaban—an oral, direct factor Xa inhibitor—in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 47(3):203–216. https://doi.org/10.2165/00003088-200847030-00006 CrossRefGoogle Scholar
- 14.Kubitza D, Becka M, Zuehlsdorf M, Mueck W (2006) Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46(5):549–558. https://doi.org/10.1177/0091270006286904 CrossRefGoogle Scholar
- 15.Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W (2013) Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. https://doi.org/10.1111/jth.12149 Google Scholar
- 18.Tripodi A, Ageno W, Ciaccio M, Legnani C, Lippi G, Manotti C, Marcucci R, Moia M, Morelli B, Poli D, Steffan A, Testa S (2018) Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfus 16(5):462–470. https://doi.org/10.2450/2017.0124-17 Google Scholar
- 21.Kim B, Jang S, Lee YJ, Park N, Cho YU, Park CJ (2019) The rivaroxaban-adjusted normalized ratio: use of the prothrombin time to monitor the therapeutic effect of rivaroxaban. 76(3):122–128. https://doi.org/10.1080/09674845.2019.1605648
- 22.Park SH, Seo YH, Park PW, Kim KH, Seo JY, Lee HT (2019) Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: experience at a single institution. 33(5):e22869. https://doi.org/10.1002/jcla.22869
- 23.Tripodi A, Chantarangkul V, Guinet C, Samama MM (2011) The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 9(1):226–228. https://doi.org/10.1111/j.1538-7836.2010.04106.x CrossRefGoogle Scholar
- 24.Harenberg J, Marx S, Kramer R, Giese C, Weiss C (2011) Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis Int J Haemost Thromb 22(8):637–641. https://doi.org/10.1097/mbc.0b013e328349f1d6 CrossRefGoogle Scholar